381 related articles for article (PubMed ID: 11309296)
1. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
Wu HY; Kang YJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):515-20. PubMed ID: 9808675
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes.
Wang GW; Klein JB; Kang YJ
J Pharmacol Exp Ther; 2001 Aug; 298(2):461-8. PubMed ID: 11454906
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels.
Wang GW; Kang YJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):938-44. PubMed ID: 10027829
[TBL] [Abstract][Full Text] [Related]
6. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS
Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496
[TBL] [Abstract][Full Text] [Related]
7. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity.
DiSilvestro RA; Liu J; Klaassen CD
Res Commun Mol Pathol Pharmacol; 1996 Aug; 93(2):163-70. PubMed ID: 8884987
[TBL] [Abstract][Full Text] [Related]
9. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine.
Abd El-Gawad HM; El-Sawalhi MM
J Biochem Mol Toxicol; 2004; 18(2):69-77. PubMed ID: 15122648
[TBL] [Abstract][Full Text] [Related]
12. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice.
Fu Z; Guo J; Jing L; Li R; Zhang T; Peng S
Toxicol In Vitro; 2010 Sep; 24(6):1584-91. PubMed ID: 20600803
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity.
Khan M; Shobha JC; Mohan IK; Naidu MU; Sundaram C; Singh S; Kuppusamy P; Kutala VK
Phytother Res; 2005 Dec; 19(12):1030-7. PubMed ID: 16372368
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts.
Kang YJ; Sun X; Chen Y; Zhou Z
Chem Res Toxicol; 2002 Jan; 15(1):1-6. PubMed ID: 11800590
[TBL] [Abstract][Full Text] [Related]
15. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.
Cai L; Wang Y; Zhou G; Chen T; Song Y; Li X; Kang YJ
J Am Coll Cardiol; 2006 Oct; 48(8):1688-97. PubMed ID: 17045908
[TBL] [Abstract][Full Text] [Related]
16. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.
Zhou G; Li X; Hein DW; Xiang X; Marshall JP; Prabhu SD; Cai L
J Am Coll Cardiol; 2008 Aug; 52(8):655-66. PubMed ID: 18702970
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
18. Prior increase in metallothionein levels is required to prevent doxorubicin cardiotoxicity.
Sun X; Kang YJ
Exp Biol Med (Maywood); 2002 Sep; 227(8):652-7. PubMed ID: 12192109
[TBL] [Abstract][Full Text] [Related]
19. [Metallothionein inhibited DOX-induced cardiac apoptosis in mice].
Shuai Y; Guo J; Peng SQ; Zhang LS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):620-3. PubMed ID: 17718425
[TBL] [Abstract][Full Text] [Related]
20. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
Jagetia GC; Reddy TK; Malagi KJ; Nayak BS; Naidu MB; Ravikiran PB; Kamath SU; Shetty PC; Reddy DS
Phytother Res; 2005 Sep; 19(9):772-8. PubMed ID: 16220569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
